Evidence map›Paper›PMID 26759813›Full record

ArticleJournal of diabetes research2016

Exenatide Activates the APPL1-AMPK-PPARα Axis to Prevent Diabetic Cardiomyocyte Apoptosis.

Lei XiaoTian, Wu QiNan, Gan XiaGuang, Deng WuQuan, Chen Bing, Liang ZiWen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Type 2 Diabetes From the Perspective of Telomere Biology.Endocrinology, diabetes & metabolism · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lei XiaoTianEndocrine Department, The First Affiliated Hospital of the Third Military Medical University, Chongqing 400038, China.
Wu QiNanEndocrine Department, The First Affiliated Hospital of the Third Military Medical University, Chongqing 400038, China.
Gan XiaGuangEndocrine Department, The First Affiliated Hospital of the Third Military Medical University, Chongqing 400038, China.
Deng WuQuanEndocrine Department, The First Affiliated Hospital of the Third Military Medical University, Chongqing 400038, China.
Chen BingEndocrine Department, The First Affiliated Hospital of the Third Military Medical University, Chongqing 400038, China.
Liang ZiWenEndocrine Department, The First Affiliated Hospital of the Third Military Medical University, Chongqing 400038, China.
Army Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the effect and mechanism of the exenatide on diabetic cardiomyopathy.

methodsRats were divided into control group, diabetes group (D), diabetes treated with insulin (DI) group, and diabetes treat with exenatide (DE) group. We detected apoptosis rate by TUNEL, the adiponectin and high molecular weight adiponectin (HMW-adiponectin) by ELISA, and the expression of APPL1, p-AMPK/T-AMPK, PPARα, and NF-κB by immunohistochemistry and western blotting.

resultsCompared with the D group, the apoptosis in the Control and DE groups was decreased (P < 0.05); the adiponectin and HMW-adiponectin were increased (P < 0.05); the APPL1, p-AMPK/T-AMPK, PPARα, and LV -dP/dt were increased (P < 0.05); and the NF-κB, GRP78, and LVEDP were decreased (P < 0.05). Compared with DE group, the glucose levels in the DI group were similar (P < 0.05); the apoptosis and LVEDP were increased; the APPL1, p-AMPK/T-AMPK, PPARα, and LV -dP/dt were decreased (P < 0.05); the NF-κB and GRP78 were increased (P < 0.05); the adiponectin and HMW-adiponectin were significantly decreased (P < 0.05).

conclusionOur model of diabetic cardiomyopathy was constructed successfully. After being treated with exenatide, the adiponectin and HMW-adiponectin and the APPL1-AMPK-PPARα axis were increased, the NF-κB and the apoptosis were decreased, the cardiac function of the diabetic rats was improved, and these effects were independent of glucose control.

Indexed as

Adaptor Proteins, Signal TransducingAdenylate KinaseAnimalsApoptosisBlood GlucoseDiabetes Mellitus, Type 2ExenatideHypoglycemic AgentsInsulinMaleMyocytes, CardiacNerve Tissue ProteinsPeptidesPhosphorylationPPAR alphaRatsAdaptor Proteins, Signal TransducingAdenylate KinaseAppl1 protein, ratBlood GlucoseExenatideHypoglycemic AgentsInsulinNerve Tissue ProteinsPeptidesPPAR alphaVenoms

Identifiers

PMID26759813
PMCPMC4677202
OpenAlexW1530989186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.